Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR)
© Heublein et al.; licensee BioMed Central Ltd. 2013
Received: 10 December 2012
Accepted: 11 January 2013
Published: 22 January 2013
Anti-Her-2 treatment is successfully administered to Her-2 overexpressing breast cancer patients and significantly implicates upon their survival. Building on these promising results, anti-Her-2 treatment protocols were tested as an option for epithelial ovarian cancer (EOC) as well. However Her-2 signalling is known to be modulated by G-protein coupled receptors (GPCR). Since a common GPCR in ovarian cancer is the FSH receptor (FSHR), we investigated the prognostic significance of Her-2 in patients that had been stratified according to their FSHR status.
A total number of 153 EOC patients were included in this study. Her-2 positivity was assessed using a standard protocol. Intriguingly Her-2 turned out to be an independent prognostic marker for poor overall survival only in those patients that did not express FSHR. This did neither apply for the whole panel nor in case of FSHR co-expression.
We thus conclude that Her-2 can be a negative prognosticator only in FSHR negative EOC cases. Hence by stratifying EOC patients according to their FSHR expression status, we introduce a diagnostic protocol to effectively select EOC patients that would most probably respond to anti-Her-2 treatment. This observation could be of clinical importance in terms of selecting the patient that would most likely benefit from anti-Her-2 treatment.
KeywordsHer-2/neu Follicle stimulating hormone receptor Ovarian cancer Prognosis
Receptor tyrosine-protein kinase erbB-2
Follicle stimulating hormone receptor
Luteinizing hormone receptor
Epidermal growth factor receptor
Immuno reactive score
Epithelial ovarian cancer
Formalin fixed paraffin embedded
Fluorescence in situ hybridisation
Food and drug administration
International Federation of Gynecology and Obstetrics.
The anti-Her-2 treatment is widely accepted in treating Her-2 expressing breast carcinoma cases, with a significant implication upon their survival . These successful results triggered the optimistic hypothesis that anti-Her-2 treatment could be an option against any carcinoma expressing Her-2. The last decade epithelial ovarian cancer (EOC) has been reported as potentially Her-2 expressing, with a positivity ranging from 4.9% to 70.4% [2, 3]. However its role in EOC survival is at least controversial. Despite this controversy and due to the significant impact of anti-Her-2 treatment on breast cancer, several groups have studied the role of trastuzumab or pertuzumab in Her-2 expressing EOC patients [4, 5]. Interestingly, Her-2 has been reported as interacting with G-protein coupled receptors (GPCRs), both at a signalling and an extracellular level . Of note is the fact that EOC has been reported as widely expressing follicle stimulating hormone receptor (FSHR) . The FSHR expression has been found as a negative prognosticator in EOC patients . Considering the interaction of Her-2 and FSH as possible, we have studied the effect of Her-2 in survival of EOC patients by stratifying them according to their FSHR status.
Patients and methods
Formalin fixed paraffin embedded (FFPE) tissue of 153 EOC patients (mean age: 58.71 years) who had undergone surgery for EOC from 1990 to 2002 at our department were analysed. Histological characterization (serous: n = 108, mucinous: n = 12, endometrioid: n = 21, clear cell: n = 12) and WHO tumour grading (G1: n = 36, G2: n = 52, G3: n = 53) was performed by an experienced gynaecological pathologist (DM). Data on FIGO stage (I: n = 34, II: n = 9, III: n = 102, IV: n = 3) and survival (median: 3.41 years; deaths: n = 103) were available. Patients staged as FIGO II - IV received carboplatin/paclitaxel as an adjuvant chemotherapy. The study was carried out in compliance with the guidelines of the Helsinki Declaration (1975) and was approved by the Ethics Committee of the Ludwig-Maximilians-University of Munich.
FFPE ovarian cancer samples were stained using an FDA-approved Ventana PATHWAY anti-Her-2 (4B5) Rabbit monoclonal antibody (Roche, Mannheim, Germany) on a VENTANA®-Unit (Roche, Mannheim, Germany) and scored as recommended by the manufacturer as 3+, 2+, 1+ or 0 by two blinded independent observers including a gynaecological pathologist (DM) by consensus. Cases that were scored as 2+ underwent fluorescence in situ hybridisation (FISH) as described previously . Immunohistochemical staining for the FSH receptor was assessed as already described by our group . For survival analysis, samples expressing Her-2 at 1+, 2+ or 3+ on a protein level were scored as positive while median FSHR receptor expression (IRS = 3) was used as a cut off to define FSHR positive vs. negative tumours. Gamma/Spearman coefficients, uni- and multivariate survival analysis were employed for statistical analysis. Statistical significance for all tests was set as p < 0.05.
The role of Her-2 in EOC is still unclear. Several studies support a potential role upon EOC survival  while others consider it as not being related to prognosis . This can be mainly attributed to the fact that up to-date there is no consensus about the evaluation protocol applied for Her-2 overexpression in EOC. The situation became even more complex due to the fact that different antibodies are used. It can thus be concluded that regarding Her-2 in EOC there is a far more imperative need at least for a consensus in the way Her-2 overexpression will be evaluated.
The existing reports upon efficacy of anti-Her-2 treatment in ovarian cancer patients are few and not encouraging, mainly because the response rate was rather low [4, 5]. Such finding though can be explained possibly by the hypothesis that other molecular pathways interfere with the EGFR/Her-2 signalling [6, 10], potentially minimizing Her-2 impact on ovarian cancer cell proliferation and ultimately to the Her-2 effect on disease progression and prognosis.
Herein we hypothesized that such interference could involve the FSHR and its downstream signalling. Although FSHR-expressing EOC patients have been shown to be of worse prognosis compared to FSHR non-expressing EOC patients , an effective selective anti-FSHR intervention has not been published so far. Several clinical trials using anti-gonadotropin receptor (GnR) agents have failed to demonstrate a significant improvement in EOC patient survival [11, 12], most possibly due to the fact that such treatments target simultaneously the luteinizing hormone receptor (LHR) as well, a receptor being a positive prognosticator for EOC survival. Thus, anti-GnR failure can be attributed to the combined cancelling of a negative and a positive prognosticator.
Despite the failure of anti-GnR treatment, the idea of using FSHR - a negative prognosticator for EOC - as a stratifying factor in order to evaluate Her-2 impact on EOC survival, is still appealing. Most possibly FSHR signalling by interfering with Her-2 could abrogate Her-2 signalling and thus its effect on survival. The results presented herein verify this hypothesis. Only in FSHR negative EOC cases does the Her-2 expression present a significant negative impact on patient survival. Of course it could be argued that the sample size of Her-2 positive cases presented herein is rather small. We would agree on such comment, highlighting at the same time though the fact that Her-2 expression in EOC is also restricted. Additionally, by dissecting the Her-2 expressing cases into FSHR positive and negative, we provide an explanation for the restricted impact of anti-Her-2 treatment in EOC. It can be hypothesized that it is likely for EOC patients with the specific phenotype (FSHR negative/Her-2 positive) to benefit from anti-Her-2 treatment. Since, though such patients consist a very small proportion of EOC patients (in our series 3 out of 153), a multicentre clinical study would be necessary to obtain an adequate sample to prove in a statistically significant way whether our current findings and hypothesis are of clinical importance.
In the current report it is demonstrated that Her-2 can be a negative prognosticator only in FSHR negative EOC cases. This observation could be of clinical importance in terms of selecting the patient that would probably benefit from anti-Her-2 treatment. Hence by stratifying EOC patients according to their FSHR expression status, we introduce a diagnostic protocol to effectively select EOC patients that would most probably respond to anti-Her-2 treatment. This observation could be of clinical importance in terms of selecting the patient that would most likely benefit from anti-Her-2 treatment. However due to the small incidence of the FSHR positive/Her-2 negative phenotype in EOC a multicentre study is necessary to verify our result and - as a second step - to assess anti-Her-2 treatment efficacy.
Udo Jeschke and Darius Dian share senior authorship.
The authors thank Christina Kuhn and Simone Hofmann for their excellent technical assistance.
- Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, et al.: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011,12(3):236–244.PubMedView Article
- Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB: Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 2005,24(2):147–152.PubMedView Article
- Hung MC, Zhang X, Yan DH, Zhang HZ, He GP, Zhang TQ, Shi DR: Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 1992,61(2):95–103.PubMedView Article
- Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, et al.: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005,23(11):2534–2543.View Article
- Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003,21(2):283–290.View Article
- Daub H, Weiss FU, Wallasch C, Ullrich A: Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996,379(6565):557–560.PubMedView Article
- Lenhard M, Lennerova T, Ditsch N, Kahlert S, Friese K, Mayr D, Jeschke U: Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology 2011,58(6):990–994.PubMedView Article
- Engelstaedter V, Boda J, Volklein C, Engel J, Jeschke U, Kirchner T, Mayr D: Lack of prognostic relevance of Her-2/neu, topoisomerase IIalpha and EGFR in advanced ovarian carcinoma. Experimental and therapeutic medicine 2012,3(5):828–834.PubMedPubMed Central
- Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E: HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Annals of oncology : official journal of the European Society for Medical Oncology/ESMO 2004,15(1):104–112.View Article
- Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, Lefkowitz RJ, Luttrell LM: The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 2000,275(13):9572–9580.PubMedView Article
- Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, et al.: A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007,110(11):2448–2456.PubMedView Article
- Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson GC: Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 2005,93(6):647–651.PubMedView ArticlePubMed Central
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.